Aspire BioPharma

Disruptive technology that improves medicine effectivess safely and rapidly

Claim My Business
Min Investment
Offering Date
October 31, 2023
Expected Close Date
February 01, 2024
No. Investors
Security Price

Company Description

Disclosures & Disclaimers

OpenDeal Broker LLC charges you a two percent (2%) administrative fee on the gross principal transaction with a minimum fee of $5 and a maximum of $300. The fee is added to the total amount of your investment at checkout.

Past financial results are no guarantee of future performance. Click here for important information regarding Financial Projections which are not guaranteed.

Key Deal Facts

Innovation in Medicine Intake
Patent Protected Technology
Our first product will be Instaprin
Fighting the Opioid Crisis
$100B Addressable Market

Management Team / Advisory Board Bios

Kraig Higginson
CEO & Chairman of the Board

Ernest Scheidemann

Stephen Quesenberry
General Counsel

Dr. James K. Dzandu
Medical Advisor

Paul Montanarella, MD
Medical Advisor

Jeffrey Barletta, PharmD, FCCM
Medical Advisor

Lance Friedman
Director of Investor Relations

Morhaf Ibrahim, MD, FHRS, FACC
Medical Advisor

Edward Kimball, MD
Medical Advisor

Gary Bernard, MD
Medical Advisor

John A. Mansour Jr, DO
Medical Advisor
Amount Raised : $228,392
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Research Reports

No reports have been submitted

Become a Reporter